HomeAbout UsNew Stock AlertsFeatured ReportsDisclaimerContact Us
FREE Stock Alerts!
Get Our 100% Free
Featured Stock Alerts Newsletter.
Enter Your Email:
Sign Up Today for our Free OTC Stock Alerts Newsletter. Free Market Analysis on the Fastest Growing Stocks producing the Highest Yields and News about Companies with the Highest Potential for Gains!

PROTON LABORATORIES, INC.
Stock Symbol :: PLBI
E-Mail this Article to a Friend
Print this Article
PROTON LABORATORIES, INC. (PLBI)

Proton Laboratories, Inc., through the acquisition of Regenobody S.A., a Dominican Republic company, is involved in some of the latest technologies associated with stem cell regeneration using the patient's own stem cells.
Recent Price
Market Capitalization $1.08M
Est Float 36M
Outstanding Shares 56M
Quotation OTC.PK

Proton Laboratories, Inc.

1135 Atlantic Avenue
Alameda, CA 94501



Phone: 888-548-3002
Fax: 888-548-3004
http://www.regenobody.com
Similar Companies in Sector

  ·         Stem Cell Therapy International, Inc. is a development-stage company. The Company is engaged in the licensing of stem cell technology, the sale of stem cell products, and the referral of patients to affiliated stem cell clinics through its wholly-owned subsidiary Stem Cell Therapy International Corp. OTCBB:SCII Recent Price: $.112

 ·         International Stem Cell Corporation, incorporated is a biotechnology company. The Company is focused on developing therapeutic products and research products. It is in development-stage. The Company’s objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease, corneal disease, and retinal disease through cell transplant therapy. OTCBB: ISCO Recent Price: $.83



Current Projects

Proton Laboratories, Inc. Announces the Acquisition of Regenobody S.A.

Proton Laboratories, Inc. has announced the acquisition of Regenobody S.A., a Dominican Republic company involved in some of the latest technologies associated with stem cell regeneration using the patient's own stem cells. Pursuant to the Agreement, the Company (PLBI) will issue 300,000,000 of its common shares to the Regenobody shareholders, which will result in the shareholders of Regenobody acquiring shareholder control of Proton Laboratories, Inc. It is anticipated that a name change and symbol change will occur in the next 90 days.

 PLBI/RegenoBody Announces Filing of Additional Information on OTC Markets.com

 Proton Laboratories, Inc. (Pink Sheets:PLBI - News) announced that it has posted additional information on OTCMarkets.com (formerly pinksheets.com) relating to its 12/31/09 balance sheet status having engaged the accounting firm of Davis Sita & Company P.A. of Greenbelt Maryland. We are working to bring all historical financial information together for 2009 and 2008 as required by OTCMarkets' guidelines by month end as we obtain additional data from past management. 

REGENOBODY S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most potent cells in the world, today



Company Overview

Proton Laboratories, Inc. (OTC.PK: PLBI)

REGENOBODY IS A WORLD LEADER IN STEM CELLS TREATMENTS

By applying the regenerative powers of stem cells, REGENOBODY AGE REVERSAL achieves the target of halting the ageing degenerative process, improving the quality of life of people willing to maintain a young look and a real rejuvenation in the inside, with better functioning, re-energized and healthy organs.

REGENOBODY THERAPEUTIC brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options.

Many different conditions can be successfully addressed using their special Stem Cell Therapies. Their institute utilizes the most potent cells in the world, today. Therapies are tailored for each individual, based upon their specific needs. Cells they use are obtained by the most modern technologic method. Their transplant physicians and stem cell laboratory scientists are the most experienced and are regarded as the best in the world.

Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated.

Patients can rest assured that they will be receiving the most efficacious Stem cell transplant in one of the world's most modern and well equipped facilities.

Treatments are delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care. The journey toward new youth and wellness will begin with begins with the initial phone call and continues throughout treatment at one of their centers.

Their Therapeutics and Regenerative Evaluation Centers:

• REGENOBODY INSTITUTE, Sosua, Dominican Republic.

• HOSPITAL: CENTRO MEDICO DE LA COSTA NORTE Sosua, Dominican Republic 

• REGENOCLINIX HEALTH INSTITUTE, Sosua, Dominican Republic

 

The Centers are comprised of a complete diagnostic, outpatient facilities, including:

·         Cardiac Catheterization Lab 

·         Carboxy therapy 

·         Cells quality evaluation

·         Kelation therapy

·         Neurotoxins elimination 

·         Oxygen therapy

·         Peripheral Vascular Ultrasound 

·         Stress testing 

·         Vacuum therapy 

 

There the patient undergoes all the necessary pre-treatment tests and protocols that will better his/her general health conditions prior to receiving the stem cell transplant.

The "Initial Evaluation" to determine if they would benefit from the treatments, will be given prior to traveling to their facilities after a review of their medical records, conducted by the doctors in conjunction with their personal physician.

After the treatment there is usually no need to stay at the hospital/clinic, so patients can choose to stay with family in one of their enchanting hotels: Sosua Bay and Victorian House or in an apartment at their Sosua Paradise "apartments only" Hotel.

 

Stem Cell Therapy

Adult Stem Cell Therapy is safe, highly effective and presents minimal risk. It begins with a complete medical evaluation performed by the patient's personal doctor, who will use the necessary documentation sent by them, to determine the patient's overall health and eligibility for therapy.

Once qualified, Adult Stem Cells are extracted from the patient's own blood and/or fat, via a standard draw procedure. Since it is the patient's own cells, there is no possibility of the body rejecting its own stem cells. This makes the procedure very safe and non-controversial. The few naturally occurring stem cells are then cultivated into millions of RegenoCells.

The RegenoCell are then sent to their Clinics in Sosua and re-injected back into the patient's via an IV or IM injection. There they stimulate tissue re-growth and greater blood flow to the affected areas. Because RegenoCells are extracted from the patient's own body they cannot be rejected by the patient's body.

A full report is prepared by the treating physician.  Follow-up exams will be handled in the Dominican Republic at their RegenoBody Clinical Center, and all medical information is provided to the patient’s personal physician.

The treatment is not a cure, IT IS A PROCESS OF REPAIR, that occurs at varying levels. Repeat treatments may be necessary in certain cases : this will be discussed with the patient before initiating treatment.

The RegenoBody Process

Once a patient qualifies for treatment, the following steps will apply to easily accompany them throughout the journey to wellness.

Before Arriving in the Dominican Republic

• They will determine to use the patient’s blood or adipose or Regenobody`s stem cells.
• If using the patient’s stem cells, they will be  drawn locally and sent to their lab.
• At the lab, the stem cells are cultivated into millions.
• As soon as the cultivating process will be complete, the patient
   will travel to Regenobody Institute facilities in Sosua, Dominican Republic.

Traveling to the Dominican Republic

• The patient will land in Puerto Plata’s International airport which is only 5 miles
   distance from Sosua.
• At the airport, the patient will be greeted by a personal representative of the RegenoBody institute.  This representative will provide 24-hours assistance during the patient's stay in the  Dominican Republic.
 
      * transportation to and from the airport
      * language interpretation
      * clinics and hotel check-in.

• The patient will be treated at the Regenobody Institute, a full service medical clinic, providing anti-ageing and regenerative treatments to patients of all ages.

• After the treatment, the patient will recover at the Sosua Bay Hotel or at the Victorian House Hotel,    which are adjacent to the clinics and face the beautiful bay of Sosua.
 

Recovery time

• Rejuvenating and PAD patients will only need 2-3 hours rest to recover.
• Cardiac patients will spend up to 48 hours at the hospital.
• Patients are encouraged to relax for the days following treatment and
   not fly back home immediately in order to receive the post-transplant protocols

 Leadership

Armando Casciati, President

Jim Wheeler, CEO

 



Market Snapshot

 



News

No News Releases Found.

Disclosure

OTCReporter.com and HotOTCChina.com are owned by Oceanic Consulting, LLC ("Oceanic") and Garden State Resources NJ, LLC ("Garden State"), both of which are New Jersey limited liability corporations (OTCReporter.com and Hot OTCChina.com and its owners, Oceanic and Garden State, and their affiliates, directors and officers and immediate family members are referred to in our Disclaimer as "OTCR" or "we" or "us" or "our). Oceanic and Garden State are referred to herein collectively as the "LLC Companies" when the context of the statements pertain to compensation matters, including our "Compensation Disclosure" section that seeks to comply with Section 17(b) of the1933 act, as amended, which states that any person who disseminates publications or other communications (through interstate commerce) for consideration received or to be received, directly or indirectly, from an issuer, underwriter, or dealer, must disclose the receipt and amount, whether past or prospective, of such consideration. The LLC Companies received four million one hundred sixty six thousand six hundred sixty seven of free trading shares and twenty five thousand dollars from a non-affiliate third party shareholder of PLBI in return for OTCR’s services to publicly and electronically disseminate information pertaining to PLBI,and thereafter sold all four million one hundred sixty six thousand six hundred sixty seven free trading shares. It is imperative that all readers of the above Compensation Disclosure Section click on the link below to carefully review our Disclaimer in its entirety, which contains important information about penny stocks, our operations, the limited nature of the information presented in our publications and various risks attendant to the companies that we profile.

Click to read our disclaimer


Home   -   About Us   -   New Stock Alerts   -   Featured Reports   -   Disclaimer   -   Contact Us
© 2004-2006 OTCReporter.com, All rights reserved.